Arcus Biosciences (RCUS) financial statements
Arcus Biosciences reported revenue of $247M in fiscal 2025, up 90.7% a year over 8 years.
Net income was -$353M.
Free cash flow was -$484M.
The diluted share count rose 12331% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Arcus Biosciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1M | $8M | $15M | $78M | $383M | $112M | $117M | $258M | $247M |
| Research and development | $14M | $47M | $50M | $78M | $159M | $257M | $288M | $340M | $448M | $523M |
| Selling, general and admin | $4M | $8M | $14M | $25M | $43M | $72M | $104M | $117M | $120M | $110M |
| Operating income | -$18M | -$53M | -$55M | -$89M | -$124M | $54M | -$280M | -$340M | -$330M | -$386M |
| Interest expense | — | — | — | — | — | — | $2M | $2M | $4M | $8M |
| Pre-tax income | — | — | — | -$85M | -$123M | $55M | -$266M | -$301M | -$282M | -$353M |
| Income tax | — | — | — | — | — | $2M | $1M | $6M | $1M | $0 |
| Net income | -$18M | -$53M | -$50M | -$85M | -$123M | $53M | -$267M | -$307M | -$283M | -$353M |
| EPS (diluted) | -$20.80 | -$29.03 | -$1.43 | -$1.93 | -$2.24 | $0.71 | -$3.71 | -$4.15 | -$3.14 | -$3.29 |
| Diluted shares | 1M | 2M | 35M | 44M | 55M | 74M | 72M | 74M | 90M | 107M |
| Operating margin | — | -3782.1% | -656.8% | -591.4% | -159.0% | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Net margin | — | -3756.7% | -593.7% | -564.7% | -157.7% | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
Balance sheet
Fiscal years, from Arcus Biosciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $65M | $176M | $257M | $188M | $729M | $499M | $1.0B | $759M | $978M | $981M |
| Total current assets | — | $177M | $259M | $193M | $736M | $1.3B | $1.1B | $831M | $1.0B | $1.0B |
| Property, plant and equipment | — | $11M | $11M | $9M | $11M | $32M | $35M | $51M | $47M | $40M |
| Total assets | — | $190M | $275M | $203M | $772M | $1.6B | $1.3B | $1.1B | $1.1B | $1.1B |
| Total current liabilities | — | $13M | $17M | $23M | $122M | $166M | $193M | $184M | $226M | $231M |
| Total liabilities | — | $37M | $40M | $39M | $270M | $750M | $688M | $633M | $665M | $508M |
| Shareholders' equity | -$20M | -$72M | $235M | $164M | $502M | $842M | $657M | $462M | $485M | $631M |
| Net debt | -$65M | -$98M | -$71M | -$58M | -$173M | -$148M | -$206M | -$127M | -$150M | -$222M |
Cash flow
Fiscal years, from Arcus Biosciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13M | -$25M | -$43M | -$73M | $111M | -$256M | $438M | -$306M | -$170M | -$482M |
| Capital spending | $4M | $6M | $4M | $2M | $3M | $26M | $6M | $24M | $6M | $2M |
| Free cash flow | -$17M | -$31M | -$47M | -$75M | $108M | -$282M | $432M | -$330M | -$176M | -$484M |
| Stock-based compensation | $90,000 | $495,000 | $4M | $9M | $22M | $55M | $65M | $73M | $76M | $60M |
| Share buybacks (net) | — | — | $0 | -$94,000 | — | — | — | — | — | — |
| Net borrowing | — | — | — | — | — | — | $0 | $0 | $47M | $49M |
| Free cash flow margin | — | -2163.7% | -559.5% | -502.6% | 138.5% | -73.6% | 385.7% | -282.1% | -68.2% | -196.0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RCUS.
Open RCUS in InvestinglyQuestions
What was Arcus Biosciences's revenue in 2025?
$247M in fiscal 2025, from its 10-K filing.
How much free cash flow does Arcus Biosciences generate?
-$484M in fiscal 2025 (operating cash flow minus capital spending).
From Arcus Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.